Turning Leukemia into a Highly Treatable Disease
Chemotherapy is a standard treatment for the most common form of leukemia — chronic lymphocytic leukemia (CLL). A combination of pills may offer CLL patients new, better and gentler options.
Hodgkin Lymphoma Treatment May Boost Breast Cancer Risks
The vast majority of children who develop Hodgkin lymphoma beat the blood cancer after treatment, which includes powerful radiation. A new study looked at how that therapy affected young patients later in life.
Rx May Offer Hope for Some Non-Hodgkin Lymphoma Patients
Most patients with a slow-growing form of non-Hodgkin lymphoma respond well to therapy at first. But the disease can return and become resistant to therapy. A new medication may change this pattern.
Non-Hodgkin Lymphoma Rx Reduced Tumors
A new type of medication that disables lymphoma tumor cells has shown considerable success for patients who were not responding to other treatments.
Using Genetic Engineering to Treat Cancer
Many leukemias can be treated successfully, but if the disease doesn’t respond, patients are left with few options. A new therapy may change all that.
It Took Two to Fight Lymphoma
Treatment for follicular lymphoma — the most common type of non-Hodgkin lymphoma — often comes with serious side effects. New research may change that for many patients.
Reducing Discomfort of Leukemia Treatment
While leukemia treatments can be uncomfortable, they also save lives. Still, reducing the discomfort of these treatments remains important, especially for the youngest patients.
Study Finds Promising Treatment for Myelofibrosis
Myelofibrosis is a type of chronic leukemia that attacks bone marrow. Researchers at Mayo Clinic showed promising study results for one treatment for this disease.
Banned Rx May Save Young Lives
A medication taken off the market in 2010 may have a new use in treating children with an aggressive form of blood cancer.
Rx Improved Stem Cell Transplant Success and Survival
To avoid potentially lethal complications, stem cell transplants had to use cells donated by relatives of the patient or perfectly matched donors. Not anymore. Researchers are expanding the possibilities.